精品文档---下载后可任意编辑抗 ErbB2/CD16 三价双特异性抗体的抗肿瘤作用的开题报告摘要：ErbB2 是一种细胞表面受体，在多种恶性肿瘤中过度表达。因此，抑制 ErbB2 信号通路已成为治疗肿瘤的重要策略。抗 ErbB2 单克隆抗体（mAb）已被成功地用于治疗 ErbB2 阳性的乳腺癌和胃癌。但是，抗ErbB2 mAb 也存在一些局限性，如耐药性和免疫细胞的免疫抑制作用。因此，近年来双特异性抗体（BsAb）的讨论受到了越来越多的关注。本文介绍了一种针对 ErbB2/CD16 的三价双特异性抗体（tri-specific Ab），它能够同时结合 ErbB2 和 CD16，从而激活免疫细胞的作用，增强瘤细胞的杀伤效应。与抗 ErbB2 mAb 相比，这种 BsAb 在细胞毒性方面表现更强，可以应付一些对单抗耐药的肿瘤细胞株。同时，该 BsAb 还能够抑制 Treg 细胞的免疫抑制作用，增强 CD8+T 细胞的杀伤作用，从而实现更好的治疗效果。本文所述的 tri-specific Ab，已经完成了体外实验和动物试验阶段，虽然仍需更进一步的讨论，但它有望成为一种新的治疗肿瘤的治疗方法。关键词：ErbB2，CD16，双特异性抗体，肿瘤治疗Abstract:ErbB2 is a cell surface receptor that is overexpressed in several malignancies. Therefore, inhibiting the ErbB2 signaling pathway has become an important strategy for treating tumors. Anti-ErbB2 monoclonal antibodies (mAbs) have been successfully used to treat ErbB2-positive breast and gastric cancers. However, anti-ErbB2 mAbs also have some limitations, such as resistance and immune suppression of immune cells. Therefore, in recent years, research on bispecific antibodies (BsAbs) has received increasing attention.This paper introduces a tri-specific antibody (tri-specific Ab) against ErbB2/CD16, which can simultaneously bind to ErbB2 and CD16, thereby activating the immune function of immune cells and enhancing the killing effect of tumor cells. Compared with anti-ErbB2 mAbs, this BsAb has a stronger cytotoxicity and can cope with some tumor cell lines resistant to monoclonal antibodies. At the same time, the BsAb can also inhibit the immunosuppressive effect of Treg cells and enhance 精品文档---下载后可任意编辑the killing effect of CD8+ T cells, thereby achieving a better therapeutic effect.The tri-specific Ab described in this paper has completed in vitro experiments and animal trials. Although further research is still needed, it is expected to become a new therapeutic method for treating tumors.Keywords: ErbB2, CD16, bispecific antibodies, tumor therapy
